Skip to Site Navigation Skip to main content

Kim Lab

Kim Lab group photo

What We Do

We are interested in identifying and characterizing molecular mechanisms that drive various processes behind blood clot formation and its removal. Our focus centres around the breakdown of unwanted clots, whereby various proteins and blood cells in circulation all play a role in determining the outcome. Using these discovered mechanisms, we develop assays that can be useful for diagnostics, as well as identify new potential pathways that can be targeted for management of clotting and/or bleeding disorders.

Who We Are

Information Box Group

Headshot of Paul Y. Kim

Paul Kim

PhD

Associate Professor,
Department of Medicine

Executive Director, International Society for Fibrinolysis and Proteolysis

paul.kim@taari.ca McMaster Experts Profile Google Scholar
Headshot of Chengliang (Chris) Wu

Chengliang (Chris) Wu

PhD

Research Associate,
Department of Medicine

chengliang.wu@taari.ca
Headshot of Vanessa Sabourin

Vanessa Sabourin

BScH

Research Assistant,
Department of Medicine

vanessa.sabourin@taari.ca
Headshot of Calvin H. Yeh

Calvin H. Yeh

MD, PhD, FRCPC

Clinical Fellow,
Department of Medicine

Emergency Physician, Hamilton Health Sciences

McMaster Experts Profile
Headshot of Paniz Poursharif

Paniz Poursharif

BScH

Graduate Student,
Medical Sciences

paniz.poursharif@taari.ca
Headshot of Hena Noorzada

Hena Noorzada

HBSc

Graduate Student,
Medical Sciences

hena.noorzada@taari.ca
Headshot of Ali Aftabjahani

Ali Aftabjahani

BSc, BASc

Graduate Student,
Medical Sciences

seyedmohammadali.aftabjahani@taari.ca Google Scholar
Headshot of Savas Kim

Savas Kim

Undergraduate Student,
BHSc (Hons)

kim47@mcmaster.ca
Headshot of Michelle Vong

Michelle Vong

Undergraduate Student,
BSc (Hons)

vongm1@mcmaster.ca

Gallery

Kim Lab group photo

Projects

  1. Identifying the mechanism of how platelets regulate fibrinolysis
  2. Developing a functional platelet assay that can quantify hemostatic and fibrinolytic potential of platelets that is conferred specifically upon thrombin-mediated stimulation
  3. Characterization of coagulopathy during cardiac arrest using porcine model
  4. Developing a point-of-care assay for quantifying tranexamic acid levels in plasma and blood
  5. Identifying biomarkers of coagulopathy and fibrinolysis in acute and long COVID-19 that can predict patient clinical course and outcome

Select Publications

  1. Chessum JE, Shaya SA, Rajab D, Zhou J, Weitz JI, Gross PL, Kim PY. (2023) Thrombin activatable fibrinolysis inhibitor alters thrombus stability and pulmonary embolism burden in a sex-dependent manner in murine venous thromboembolism. Journal of Thrombosis and Haemostasis. In Press.
  2. Zheng Z, Mukhametova L, Boffa MB, Moore EE, Wolberg AS, Urano T, Kim PY. (2023) Assays to quantify fibrinolysis – strengths and limitations: Communication from the ISTH SSC Subcommittee on Fibrinolysis. Journal of Thrombosis and Haemostasis. 21(4): 1043-1054.
  3. Leong DP, Zhang A, Huynh A, Clare R, Breznik J, Muhstaha M, Rangarajan S, Stacey H, Kim PY, Loeb M, Denburg JA, Mertz D, Chagla Z, Nazy I, Miller MS, Bowdish DME, Duong M. (2023). Comparison of three dosing intervals for theprimary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude,neutralization capacity and durability of the humoral immune response in healthcare workers: a prospective cohort study. PLOS One. 18(2): e0281673.
  4. GK Juneja, M Castelo, CH Yeh, SE Cerroni, BE Hansen, JE Chessum, J Abraham, E Cani, DJ Dwivedi, DD Fraser, M Slessarev, C Martin, S McGilvray, PL Gross, PC Liaw, JI Weitz, PY Kim. (2021). Biomarkers of coagulation, endothelial functionand fibrinolysis in critically-ill patients with COVID-19: A single-centre prospectivelongitudinal study. Journal of Thrombosis and Haemostasis. 19(6):1546
  5. Cani E, Dwivedi DJ, Liaw KL, Fraser DD, Yeh CH, Martin C, Slessarev M, Cerroni SE, Fox-Robichaud AA, Weitz JI, Kim PY, Liaw PC. (2021). Immunothrombosis biomarkers for distinguishing coronavirus disease 2019 patients from noncoronavirus disease septic patients with pneumonia and for predicting ICU mortality. Critical Care Explorations. 3(12): e0588.
  6. Yeh CH, de Wit K, Levy JH, Weitz JI, Vaezzadeh N, Liaw PC, Fox-Robichaud A, Soliman K, Kim PY. (2020). Hypercoagulability and coronavirus disease 2019–associated hypoxemic respiratory failure: Mechanisms and emerging management paradigms. Journal of Trauma and Acute Care Surgery. 89(6):e177.
  7. Ni R, Neves MAD, Wu C, Cerroni SE, Flick MJ, Ni H, Weitz JI, Gross PL, Kim PY. (2020). Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin-dependent plasmin generation on thrombin-activated platelets. Journal of Thrombosis and Haemostasis. 18(9): 2364-2376.
  8. Thachill J, Longstaff C, Favaloro EJ, Lippi G, Urano T, Kim PY. (2020). The need for accurate D-dimer reporting in COVID-19: Communication from the ISTH SSC on Fibrinolysis. Journal of Thrombosis and Haemostasis. 18(9): 2408-2411.
  9. Moore HB, Gando S, Iba T, Kim PY, Yeh CH, Hunt BJ, Levy JH, Draxler DF, Stanworth S, Görlinger K, Neal MD, Schreiber MA, Barrett CD, Medcalf RL, Moore EE, Mutch NJ, Thachil J, Urano T, Thomas S, Scarlatescu E, Walsh M. (2020). Defining the coagulopathy of trauma with respect to implications for patient therapy: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 18(3): 740-747.
  10. Medeiros SK, Zafar N, Liaw PC, Kim PY. (2019). Purification of silica-free DNA and characterization of its role in coagulation. Journal of Thrombosis and Haemostasis. 17(11): 1860-5.
  11. Kim PY, Di Giuseppantonio L, Wu C, Douketis JD, Gross PL. (2019). An assay to measure levels of factor Xa inhibitors in blood and plasma. Journal of Thrombosis and Haemostasis. 17(7): 1153-1159.
  12. Friedmann AP, Koutychenko A, Wu C, Fredenburgh JC, Weitz JI, Gross PL, Xu P, Ni F, Kim PY. (2019). Identification of a factor Va-binding site on human prothrombin by the use of heteronuclear NMR and functional characterization. Scientific Reports. 9: 2436.